Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | IRAK1 | P51617 | 1/20 | 0.41 |
| ▸ | BTK | Q06187 | 8/20 | 0.40 |
| ▸ | CD38 | P28907 | 1/20 | 0.38 |
| ▸ | WDR5 | P61964 | 1/20 | 0.37 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.37 |
| ▸ | MAPK8 | P45983 | 5/20 | 0.37 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.36 |
| ▸ | MAPK3 | P27361 | 1/20 | 0.35 |
| ▸ | MAPK9 | P45984 | 4/20 | 0.35 |
| ▸ | LMNA | P02545 | 1/20 | 0.35 |
| ▸ | JAK3 | P52333 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29740638 | 0.86 | IRAK1 (0.41) | IRAK1BTKCD38MAPK8KCNH2 | |
| SCHEMBL14165965 | 0.86 | IRAK1 (0.41) | IRAK1BTKCD38MAPK8KCNH2 | |
| SCHEMBL14165369 | 0.86 | IRAK1 (0.41) | IRAK1BTKCD38MAPK8KCNH2 | |
| SCHEMBL14165368 | 0.86 | IRAK1 (0.41) | IRAK1BTKCD38MAPK8KCNH2 | |
| SCHEMBL14165782 | 0.86 | IRAK1 (0.41) | IRAK1BTKCD38MAPK8KCNH2 | |
| SCHEMBL14165818 | 0.86 | IRAK1 (0.41) | IRAK1BTKCD38MAPK8KCNH2 | |
| SCHEMBL21138338 | 0.80 | HPGDS (0.47) | KMT2ALMNA | |
| SCHEMBL30808262 | 0.80 | HPGDS (0.47) | KMT2ALMNA | |
| SCHEMBL21138216 | 0.80 | MAPK8 (0.44) | BTKMAPK8MAPK9LMNA | |
| SCHEMBL20033584 | 0.79 | BTK (0.47) | IRAK1BTKMAPK8 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3505171-A1 | BICYCLIC NITROGENATED HETEROCYCLIC COMPOUND | Mitsubishi Tanabe Pharma Corporation (JP) | 2019-07-03 | — | — | EP | disclosed |
| US-20190185479-A1 | BICYCLIC NITROGENATED HETEROCYCLIC COMPOUND | MITSUBISHI TANABE PHARMA CORPORATION (JP) | 2019-06-20 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190185479-A1 | BICYCLIC NITROGENATED HETEROCYCLIC COMPOUND | PDE7B, PDE3A, PDE7A | IRAK1 3723/4885BTK 1207/4885CD38 1096/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.